MedTrace Logo

PK/PD Study of Subcutaneous Cenderitide Infusion in CHF Patients

NCT01316432 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2012-10-18

No results posted yet for this study

Summary

The purposed of the study is to evaluate the pharmacokinetics (PK) response of continuous subcutaneous (SQ) infusion of cenderitide, as compared with a single SQ bolus.

Conditions

Interventions

DRUG

Cenderitide

Cenderitide is a novel rationally designed chimeric natriuretic peptide to be administered in this trial as either a subcutaneous injection or infusion.

OTHER

Placebo

Placebo will be administered as a 24-hour SQ infusion

Sponsors & Collaborators

  • Integrium

    collaborator INDUSTRY

  • Nile Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2011-10-31
Completion
2011-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01316432 on ClinicalTrials.gov